1. Home
  2. GKOS vs HOMB Comparison

GKOS vs HOMB Comparison

Compare GKOS & HOMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$103.72

Market Cap

6.9B

Sector

Health Care

ML Signal

HOLD

Logo Home BancShares Inc.

HOMB

Home BancShares Inc.

HOLD

Current Price

$26.28

Market Cap

6.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
HOMB
Founded
1998
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
6.0B
IPO Year
2015
2006

Fundamental Metrics

Financial Performance
Metric
GKOS
HOMB
Price
$103.72
$26.28
Analyst Decision
Strong Buy
Hold
Analyst Count
14
5
Target Price
$133.07
$32.40
AVG Volume (30 Days)
679.7K
1.3M
Earning Date
05-14-2026
04-14-2026
Dividend Yield
N/A
3.19%
EPS Growth
N/A
19.90
EPS
N/A
2.41
Revenue
$507,442,000.00
N/A
Revenue This Year
$23.39
$10.99
Revenue Next Year
$27.46
$5.14
P/E Ratio
N/A
$10.93
Revenue Growth
32.33
N/A
52 Week Low
$73.16
$24.23
52 Week High
$130.23
$30.83

Technical Indicators

Market Signals
Indicator
GKOS
HOMB
Relative Strength Index (RSI) 33.98 30.63
Support Level $81.54 $26.24
Resistance Level $106.52 $28.81
Average True Range (ATR) 3.58 0.75
MACD -1.87 -0.24
Stochastic Oscillator 10.55 6.25

Price Performance

Historical Comparison
GKOS
HOMB

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About HOMB Home BancShares Inc.

Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The bank also emphasizes attracting experienced bankers, credit quality and a solid balance sheet. The bank's main source of net revenue is net interest income.

Share on Social Networks: